



BioCorporate profile downloaded from - <http://www.bioportfolio.com> on Saturday, September 06, 2008

A&G Pharmaceutical Incorporated

[View the current A&G Pharmaceutical Incorporated Page on BioPortfolio.com](http://www.bioportfolio.com/biocomplete/18-A%26G+Pharmaceutical+Incorporated.html)

(<http://www.bioportfolio.com/biocomplete/18-A%26G+Pharmaceutical+Incorporated.html>)

Contact Details:

600E Lombard St., Suite 511

Baltimore

MD

21202

United States of America

Tel: 410-230-0901

Fax: 410-230-0903

Email: agrx@agrx.net

A&G Pharmaceutical, Inc. (A&G) was incorporated in Delaware on June 6, 2000, as a "C" Corporation, to make use of two proprietary technologies that are unique to the Company. A&G is located in Baltimore, Maryland, and consists of two distinct but integrate divisions: 1) the Pharmaceutical Division and 2) the Monoclonal Antibody Services Division.

Pharmaceutical Division

Breast cancer is the most common and most fatal malignancy for women worldwide. Overall, 15 percent of women will be diagnosed with breast cancer during their lifetime. Although breast cancer may initially be hormone-dependent and treated with anti-estrogen therapy such as tamoxifen, metastatic breast cancer will recur in 50 percent of patients within 5 years of initial treatment. The survival rate of women receiving chemotherapy is 10 to 20 percent after 5 years.

The first FDA-approved biological therapy for metastatic breast cancer, Genentech's Herceptin, was launched very successfully in 1998. Herceptin, the first antibody-based cancer therapy, is a humanized monoclonal antibody that represses erbB2. It is used as a therapeutic agent to treat patients with metastatic breast cancer over-expressing erbB2, which constitutes only 20 percent of all metastatic breast cancers. Currently, there is no similar clinical treatment for breast cancer patients not over-expressing erbB2.

Recently, A&G co-founder Dr. Ginette Serrero has cloned the novel growth factor PCDGF that is over-expressed in all metastatic breast cancers. It has been shown that inhibiting PCDGF expression or action leads to a 98 percent inhibition of human breast tumor formation in experimental animals. A&G has successfully obtained the exclusive patent rights to develop both diagnostic tools and therapeutic agents using monoclonal anti-PCDGF antibodies to address the market need for treating metastatic non-erbB2 breast cancers.

Monoclonal Antibody Services Division

A&G owns a proprietary technology that enables A&G to provide its customers the fastest monoclonal antibody production service in the industry (60 days versus an average of 180 days) and with the highest success rate (85 percent compared to an industry average of 25 percent). The Monoclonal Antibody Services Division is also developing monoclonal antibodies to key growth factors/receptors for licensing.

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's relate service indepth.

The annual cost is \$495.00 for established organizations and \$295.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2008 - BioPortfolio Limited.

